查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1715347

重症加护治疗市场按产品类型、给药途径、药物类型、治疗用途和最终用户划分－2025-2030 年全球预测

Critical Care Therapeutics Market by Product Type, Administration Routes, Drug Types, Therapeutic Application, End-User - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 198 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

重症加护治疗市场预计到 2024 年将达到 14 亿美元，到 2025 年将达到 14.8 亿美元，到 2030 年将达到 19.4 亿美元，复合年增长率为 5.49%。

主要市场统计数据
基准年2024年 14亿美元
预计2025年 14.8亿美元
预测年份 2030 19.4亿美元
复合年增长率（%） 5.49%

重症加护医学是现代医学中最具活力和变革性的领域之一，其特点是技术进步迅速、临床实践不断发展。在当今快节奏的医疗保健环境中，快速决策和有针对性的干预对于实现最佳患者治疗效果至关重要。该领域见证了技术创新和严谨临床研究的非凡融合，重新定义瞭如何在不同的医疗环境中提供重症加护。本报告首先提供了重症加护治疗的全面框架，并强调了技术和临床专业知识在管理危及生命的疾病中发挥的重要作用。

透过整合尖端技术和循证实践，该行业不断突破重症加护环境的极限。医疗设备、药物和支持性护理的进步有可能挽救生命并降低发病率。随着慢性病的增加和加护治疗需求的增加，该领域的技术创新不仅提高了患者的存活率，而且还为优质照护设定了标准。对病患管理完美的不懈追求满足了对强大即时资料的迫切需求，促进了世界各地加护病房的决策能力。

由于不断发展的临床挑战需要紧急和关键的适应，本报告提供了一个策略观点，说明相关人员如何重新构想治疗、诊断和管理严重的方法。后续章节详细介绍了格局的变革性变化，提供了跨多个参数的关键细分见解，并回顾了区域和公司趋势。这项全面的调查旨在让决策者获得细緻的了解，从而应对不断变化的重症加护治疗领域。

改变重症加护药物市场

近年来，重症加护医学领域经历了变革时期，反映了个人化和综合护理的更广泛趋势。利用即时资料和预测分析的技术正在增强传统的加护治疗模式，帮助临床医生预测併发症并迅速介入。这一演变的一个关键驱动力是先进医疗设备和数位健康解决方案的整合，从而促进对患者健康参数的持续监测。这种整合促进了重症加护的更积极主动的方法，治疗策略对患者快速变化的临床状况更具回应性。

多学科专业知识的融合进一步推动了重症加护的发展，临床医生、生物医学工程师和资料科学家共同合作创造了创新的护理模式。这种协同效应正在重塑治疗方案，并使得处理复杂的患者病例更加协调。高清影像、机器人辅助干预和智慧输液系统只是重新定义加护治疗环境中患者照护的部分技术进步。此外，采用微创技术和精准治疗方法可以降低风险、缩短恢復时间并改善整体患者体验。

治疗格局的变化不仅限于技术，还涉及监管和报销领域。政策变革和奖励主导框架正在鼓励医疗保健提供者投资先进的护理模式。此外，更重视以病人为中心的结果，确保创新与道德标准和临床效果紧密结合。因此，行业领导者现在正在重新调整其策略目标，不仅要涵盖技术优势，还要涵盖患者照护的全面改善。这些累积的进步奠定了重症加护新时代的基础，该时代强调提供及时、有效和针对患者的治疗性介入。

对市场动态的关键细分洞察

透过深入研究重症加护治疗市场的多个方面的全面細項分析，我们可以对重症监护治疗市场有更细緻的了解。根据产品类型进行细分可区分各种组件，例如植入式设备、输液袋、药物、监测设备、注射器和导管以及人工呼吸器。在这个基于产品的细分中，药物被细分为抗生素、神经肌肉阻断剂、镇静剂、溶栓剂等类别，突显了药物治疗的复杂性和专业化。

除了以产品为导向的分析外，市场还根据给药途径进行细分，治疗药物分为吸入、静脉和口服途径。每种途径都有其自身的优势和挑战，其选择受患者病情和急性护理要求的影响。细分进一步分为药物类型，区分止痛药、抗菌药和镇静剂。深入分析，止痛药分为非鸦片类镇痛药和鸦片类镇痛药，抗菌药物分为抗生素和抗病毒药物，抗生素本身又分为频谱和窄频谱。镇静剂被仔细细分为苯二氮平类镇静剂和非苯二氮平类镇静剂，并对每一类的功效和安全性进行评估。

同样重要的是基于治疗应用的细分，涵盖心血管护理、紧急復苏、神经病变、肾臟替代疗法、呼吸护理等治疗频谱。后两个领域进一步细分为神经系统疾病（透过颅内压监测和创伤性脑损伤进行评估）和呼吸照护（细分为气喘、慢性阻塞性肺病和肺水肿的管理）。最后，按最终用户细分描述了这些产品和治疗方法在不同环境中的应用，例如门诊手术中心、家庭医疗保健、医院和长期护理机构。这些全面的细分洞察不仅增强了治疗和服务的针对性，而且还推动了客製化策略以满足不同患者群体的特定需求。

目录

第一章 引言

第二章调查方法

第三章执行摘要

第四章 市场概述

第五章 市场洞察

  • 市场动态
    • 驱动程式
      • 随着人口老化，加护治疗和严重疾病的需求日益增加。
      • 提高对需要紧急治疗性介入的急性疾病的认识和诊断
    • 限制因素
      • 高昂的研发成本是重症加护医学发展的一大障碍。
    • 机会
      • 针对非侵入性严重监护监测技术的研究进行投资
      • 在严重监护环境中使用人工智慧和机器学习进行预测诊断
    • 任务
      • 对重症加护治疗领域激烈竞争和市场分化的管理担忧
  • 市场区隔分析
    • 产品类型：提高重症加护药物的製药偏好
    • 最终用户：扩大医院重症加护药物的使用
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社会
    • 技术的
    • 合法的
    • 环境

第六章重症加护治疗市场（依产品类型）

  • 嵌入式装置
  • 静脉输液袋
  • 製药
    • 抗生素
    • 神经肌肉阻断剂
    • 镇静剂
    • 纤溶药物
  • 监控设备
  • 注射器和导管
  • 人工呼吸器

第七章重症加护治疗市场（依给药途径）

  • 吸入
  • 静脉
  • 口服

第八章重症加护治疗市场（依药物类型）

  • 止痛药
    • 非鸦片类止痛药
    • 阿片类止痛药
  • 抗菌剂
    • 抗生素
      • 频谱抗生素
      • 窄效抗生素
    • 抗病毒药物
  • 镇静剂
    • 苯二氮平类药物
    • 非苯二氮平类镇静剂

第九章重症加护治疗市场（依治疗应用）

  • 心血管护理
  • 紧急復苏
  • 神经系统疾病
    • 颅内压监测
    • 创伤性脑损伤
  • 肾臟替代疗法
  • 呼吸护理
    • 气喘
    • 慢性阻塞性肺病
    • 肺水肿

第 10 章重症加护治疗市场（按最终用户）

  • 门诊手术中心
  • 家庭医疗保健
  • 医院
  • 长期照护机构

11.美洲重症加护药物市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

12. 亚太重症加护药物市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

13. 欧洲、中东和非洲重症加护药物市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十四章竞争格局

  • 2024年市场占有率分析
  • 2024年FPNV定位矩阵
  • 竞争情境分析
  • 战略分析与建议

公司名单

  • Abeona Therapeutics Inc.
  • ADMA Biologics, Inc.
  • Albumedix Ltd. by Sartorius AG
  • Asklepios BioPharmaceutical, Inc.
  • Aspen Group
  • Bio Products Laboratory Ltd.
  • BioDelivery Sciences International, Inc.
  • Biotest AG
  • CSL Limited
  • Grifols SA
  • Kedrion Spa
  • Novartis AG
  • Octapharma AG
  • Shanghai RAAS
  • Takeda Pharmaceutical Co. Ltd.
Product Code: MRR-4311CE1A33EE

The Critical Care Therapeutics Market was valued at USD 1.40 billion in 2024 and is projected to grow to USD 1.48 billion in 2025, with a CAGR of 5.49%, reaching USD 1.94 billion by 2030.

KEY MARKET STATISTICS
Base Year [2024] USD 1.40 billion
Estimated Year [2025] USD 1.48 billion
Forecast Year [2030] USD 1.94 billion
CAGR (%) 5.49%

Critical care therapeutics represents one of the most dynamic and transformative sectors in modern medicine, characterized by rapid technological advancements and evolving clinical practices. In today's fast-paced healthcare environment, rapid decisions and precise interventions are essential to achieve optimal patient outcomes. The field has witnessed an extraordinary confluence of innovation and rigorous clinical research that has redefined how critical care is delivered across diverse healthcare settings. This report starts by elucidating the overarching framework of critical care therapeutics, highlighting the integral role of technology and clinical expertise in managing life-threatening conditions.

By integrating state-of-the-art methods and evidence-based practices, the industry continues to push the boundaries of what is possible in critical care environments. Advancements in medical devices, drug therapies, and supportive care are expanding the potential to save lives and reduce morbidity. With the increasing prevalence of chronic diseases and the subsequent higher demand for intensive care, innovations in this space are not only improving patient survival rates but are also creating a benchmark for quality care. The relentless pursuit of perfection in patient management complements the critical need for robust, real-time data, fostering enhanced decision-making in intensive care units around the globe.

As evolving clinical challenges demand immediate and significant adaptation, this report provides a strategic view on how stakeholders are reshaping their approaches to therapy, diagnosis, and management of critical conditions. The subsequent sections will detail the transformative shifts in the landscape, offer key segmentation insights across multiple parameters, and review regional as well as company-specific trends. This comprehensive examination aims to equip decision-makers with the nuanced understanding needed to navigate the ever-changing realm of critical care therapeutics.

Transformative Shifts in the Critical Care Landscape

In recent years, the landscape of critical care therapeutics has undergone transformative shifts that reflect a broader trend towards personalized medicine and integrated care. The traditional model of intensive care has been augmented with technologies that leverage real-time data and predictive analytics, enabling clinicians to anticipate complications and intervene promptly. A major driver behind this evolution is the integration of advanced medical devices and digital health solutions that facilitate the continuous monitoring of patient health parameters. This integration has fostered a more proactive approach to critical care, where therapeutic strategies are now more sensitive to the rapidly changing clinical status of patients.

The evolution in critical care is further bolstered by the convergence of interdisciplinary expertise, where collaborations between clinicians, biomedical engineers, and data scientists result in innovative care models. This synergy is reshaping treatment protocols and enabling a more coordinated approach to managing complex patient cases. High-definition imaging, robotic-assisted interventions, and smart infusion systems represent just a few of the technological advances that have redefined patient care in intensive settings. Moreover, the adoption of minimally invasive techniques and precision therapeutics mitigates risks, reduces recovery times, and enhances overall patient experience.

The shifts in the therapeutic landscape are not solely confined to technology but extend into the regulatory and reimbursement territories as well. Policy changes and incentive-driven frameworks are encouraging healthcare providers to invest in advanced care models. Furthermore, the growing emphasis on patient-centric outcomes is ensuring that innovations are closely aligned with ethical standards and clinical effectiveness. As a result, industry leaders are now recalibrating their strategic goals to encompass not only technological superiority but also the holistic improvement of patient care. These collective advancements underscore a new era in critical care, where the focus is on delivering timely, efficient, and tailored therapeutic interventions.

Key Segmentation Insights in Market Dynamics

A nuanced understanding of the critical care therapeutics market is achieved through comprehensive segmentation analysis that delves into multiple dimensions of the industry. The segmentation based on product type distinguishes various components such as implantable devices, intravenous infusion bags, medications, monitoring devices, syringes and catheters, and ventilators. Within this product-based segmentation, medications receive further in-depth scrutiny by segmenting them into categories including antibiotics, neuromuscular blockers, sedatives, and thrombolytics, which underscores the complexity and specialization present within drug therapeutics.

In addition to product-oriented analysis, the market is also segmented by administration routes that categorize therapies into inhalation, intravenous, and oral pathways. Each route possesses unique merits and challenges, with choices influenced by patient conditions and acute care requirements. The segmentation further extends to drug types where distinctions are made among analgesics, antimicrobials, and sedatives. Diving deeper, analgesics are analyzed as non-opioid analgesics and opioid analgesics; likewise, antimicrobials are divided into antibiotics and antivirals, with antibiotics themselves further differentiated into broad-spectrum and narrow-spectrum types. Sedatives are carefully examined by their subclassifications into benzodiazepines and non-benzodiazepine sedatives, ensuring that each category is evaluated for both efficacy and safety.

Equally important is the segmentation based on therapeutic application which covers a spectrum of care such as cardiovascular treatment, emergency resuscitation, neurological disorders, renal replacement therapy, and respiratory care. The latter two areas receive additional granularity with neurological disorders being evaluated through intracranial pressure monitoring and traumatic brain injury, and respiratory care dissected into the management of asthma, chronic obstructive pulmonary disease, and pulmonary edema. Lastly, segmentation by end-user illustrates the application of these products and therapies in distinct settings including ambulatory surgical centers, home healthcare, hospitals, and long-term care facilities. These comprehensive segmentation insights not only enable enhanced targeting of therapies and services but also drive customized strategies to meet the specific needs of diverse patient populations.

Based on Product Type, market is studied across Implantable Devices, Intravenous Infusion Bags, Medications, Monitoring Devices, Syringes & Catheters, and Ventilators. The Medications is further studied across Antibiotics, Neuromuscular Blockers, Sedatives, and Thrombolytics.

Based on Administration Routes, market is studied across Inhalation, Intravenous, and Oral.

Based on Drug Types, market is studied across Analgesics, Antimicrobials, and Sedatives. The Analgesics is further studied across Non-Opioid Analgesics and Opioid Analgesics. The Antimicrobials is further studied across Antibiotics and Antivirals. The Antibiotics is further studied across Broad-Spectrum Antibiotics and Narrow-Spectrum Antibiotics. The Sedatives is further studied across Benzodiazepines and Non-Benzodiazepine Sedatives.

Based on Therapeutic Application, market is studied across Cardiovascular Care, Emergency Resuscitation, Neurological Disorders, Renal Replacement Therapy, and Respiratory Care. The Neurological Disorders is further studied across Intracranial Pressure Monitoring and Traumatic Brain Injury. The Respiratory Care is further studied across Asthma, Chronic Obstructive Pulmonary Disease, and Pulmonary Edema.

Based on End-User, market is studied across Ambulatory Surgical Centers, Home Healthcare, Hospitals, and Long-Term Care Facilities.

Key Regional Insights Across Global Markets

From a regional perspective, the landscape of critical care therapeutics reflects a diverse and rapidly evolving global tableau. Analysis of the Americas reveals a strong emphasis on advanced healthcare infrastructure and high investment in critical care innovation, which drives significant strides in patient management and therapeutic care. In contrast, regions classified as Europe, Middle East & Africa depict a spectrum of developments ranging from well-established healthcare systems with advanced technological adoption to emerging markets where growth is being spurred by recent investments and regulatory reforms. These regions are quickly catching up by integrating modern therapeutic solutions that enhance clinical outcomes.

Turning to the Asia-Pacific, the story is one of rapid expansion and dynamic transformation. This region is characterized by its swift adoption of novel technologies and an impressive proliferation of research and development activities. Health systems in Asia-Pacific benefit from a blend of traditional practices and contemporary innovations, resulting in tailored solutions that address both chronic and acute care challenges. The disparities in regional wealth and infrastructural capabilities lead to distinct strategic approaches in market penetration, with localized solutions often emerging to bridge gaps and ensure the widespread availability of critical care services. Overall, the regional insights demonstrate that while each geographic area has its own distinctive challenges and opportunities, all are united by the common goal of elevating critical care delivery through innovative therapeutic strategies.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

Key Companies Driving Innovation and Growth

A host of leading companies are at the forefront of transforming the critical care therapeutics landscape. Organizations such as Abeona Therapeutics Inc., ADMA Biologics, Inc., and Albumedix Ltd. by Sartorius AG are spearheading novel research initiatives and clinical applications. Equally, leaders like Asklepios BioPharmaceutical, Inc., Aspen Group, and Bio Products Laboratory Ltd. bring extensive expertise in product innovation and market expansion. Companies such as BioDelivery Sciences International, Inc., Biotest AG, and CSL Limited are providing robust frameworks for therapeutic development, further enhancing the effectiveness of complex care systems. Moreover, Grifols SA, Kedrion Spa, Novartis AG, Octapharma AG, Shanghai RAAS, and Takeda Pharmaceutical Co. Ltd. represent industry powerhouses that continue to push the envelope in terms of research excellence, rigorous quality control, and heightened patient care. The strategic collaborations and continuous investment in research and development by these companies are critical drivers in the evolution of critical care therapeutics, ensuring that the most advanced treatments and technologies consistently reach the clinical forefront.

The report delves into recent significant developments in the Critical Care Therapeutics Market, highlighting leading vendors and their innovative profiles. These include Abeona Therapeutics Inc., ADMA Biologics, Inc., Albumedix Ltd. by Sartorius AG, Asklepios BioPharmaceutical, Inc., Aspen Group, Bio Products Laboratory Ltd., BioDelivery Sciences International, Inc., Biotest AG, CSL Limited, Grifols SA, Kedrion Spa, Novartis AG, Octapharma AG, Shanghai RAAS, and Takeda Pharmaceutical Co. Ltd.. Actionable Recommendations for Market Leaders

In light of the comprehensive analysis, several actionable recommendations emerge for leaders within the critical care therapeutics industry. First, it is imperative to enhance investment in digital health and data analytics technologies that facilitate real-time decision-making in clinical settings. By leveraging predictive analytics, companies can optimize treatment protocols and improve patient outcomes. Second, fostering strategic partnerships will be critical; collaborations between device manufacturers, pharmaceutical companies, and clinical research organizations can accelerate innovation and streamline regulatory compliance.

Leaders should also consider diversifying their portfolio offerings by expanding into underpenetrated segments such as niche drug formulations and targeted therapy applications. This strategic diversification will not only mitigate risks associated with market fluctuations but also tap into unmet clinical needs. Furthermore, expanding market presence through regional diversifications, especially in emerging markets, promises untapped growth potential. Integrating localized strategies that take into account regional healthcare dynamics and regulatory environments will empower companies to tailor their product offerings more effectively.

Lastly, continuous investment in cutting-edge R&D is essential. By prioritizing the development of next-generation therapies and advanced medical devices, industry players can maintain competitive advantage and meet the evolving expectations of healthcare providers. Leaders should emphasize sustainable growth by balancing immediate market opportunities with long-term innovation strategies, ensuring that their organizations remain resilient and well-positioned in a rapidly evolving global landscape.

Conclusion and Future Outlook

The analysis presented in this report underscores a period of significant transformation in the landscape of critical care therapeutics. Technological innovations, combined with evolving regulatory frameworks and a renewed focus on patient outcomes, are collectively reshaping the future of intensive care. The multi-faceted segmentation insights and regional trends illustrate that the industry is on the cusp of embracing more personalized and efficient care models, driven by data analytics and collaborative technologies.

As the market continues to mature, stakeholders must remain cognizant of the dynamic interplay between technological advancements and the evolving clinical demands. With challenges such as rising healthcare costs and the burden of chronic diseases, the importance of precision and efficacy in critical care treatments cannot be overstated. Looking ahead, companies that embrace agility, nurture innovation, and adopt patient-centric approaches will be best positioned to capitalize on emerging opportunities. The future of critical care therapeutics is one that promises improved survival rates and enhanced quality of care, ultimately translating to better patient outcomes across all healthcare settings.

In summary, the insights derived from this comprehensive review serve as a roadmap for industry leaders aiming to secure long-term success. By aligning strategic initiatives with evolving market trends and maintaining a consistent focus on innovation, stakeholders can drive meaningful improvements in critical care delivery while simultaneously building a robust and sustainable business model.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising geriatric population contributing to higher demand for intensive and critical care services
      • 5.1.1.2. Growing awareness and diagnosis rates of acute medical conditions requiring urgent care interventions
    • 5.1.2. Restraints
      • 5.1.2.1. High research and development costs are a significant barrier in critical care therapeutics
    • 5.1.3. Opportunities
      • 5.1.3.1. Targeting investment in research for non-invasive critical care monitoring technologies
      • 5.1.3.2. Leveraging AI and machine learning for predictive diagnostics in critical care settings
    • 5.1.4. Challenges
      • 5.1.4.1. Concern associated with managing high competition and market fragmentation in the critical care therapeutics sector
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Product Type: Increasing preference for medications in critical care therapeutics
    • 5.2.2. End-User: Expanding utilization of critical care therapeutics in hospitals
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Critical Care Therapeutics Market, by Product Type

  • 6.1. Introduction
  • 6.2. Implantable Devices
  • 6.3. Intravenous Infusion Bags
  • 6.4. Medications
    • 6.4.1. Antibiotics
    • 6.4.2. Neuromuscular Blockers
    • 6.4.3. Sedatives
    • 6.4.4. Thrombolytics
  • 6.5. Monitoring Devices
  • 6.6. Syringes & Catheters
  • 6.7. Ventilators

7. Critical Care Therapeutics Market, by Administration Routes

  • 7.1. Introduction
  • 7.2. Inhalation
  • 7.3. Intravenous
  • 7.4. Oral

8. Critical Care Therapeutics Market, by Drug Types

  • 8.1. Introduction
  • 8.2. Analgesics
    • 8.2.1. Non-Opioid Analgesics
    • 8.2.2. Opioid Analgesics
  • 8.3. Antimicrobials
    • 8.3.1. Antibiotics
      • 8.3.1.1. Broad-Spectrum Antibiotics
      • 8.3.1.2. Narrow-Spectrum Antibiotics
    • 8.3.2. Antivirals
  • 8.4. Sedatives
    • 8.4.1. Benzodiazepines
    • 8.4.2. Non-Benzodiazepine Sedatives

9. Critical Care Therapeutics Market, by Therapeutic Application

  • 9.1. Introduction
  • 9.2. Cardiovascular Care
  • 9.3. Emergency Resuscitation
  • 9.4. Neurological Disorders
    • 9.4.1. Intracranial Pressure Monitoring
    • 9.4.2. Traumatic Brain Injury
  • 9.5. Renal Replacement Therapy
  • 9.6. Respiratory Care
    • 9.6.1. Asthma
    • 9.6.2. Chronic Obstructive Pulmonary Disease
    • 9.6.3. Pulmonary Edema

10. Critical Care Therapeutics Market, by End-User

  • 10.1. Introduction
  • 10.2. Ambulatory Surgical Centers
  • 10.3. Home Healthcare
  • 10.4. Hospitals
  • 10.5. Long-Term Care Facilities

11. Americas Critical Care Therapeutics Market

  • 11.1. Introduction
  • 11.2. Argentina
  • 11.3. Brazil
  • 11.4. Canada
  • 11.5. Mexico
  • 11.6. United States

12. Asia-Pacific Critical Care Therapeutics Market

  • 12.1. Introduction
  • 12.2. Australia
  • 12.3. China
  • 12.4. India
  • 12.5. Indonesia
  • 12.6. Japan
  • 12.7. Malaysia
  • 12.8. Philippines
  • 12.9. Singapore
  • 12.10. South Korea
  • 12.11. Taiwan
  • 12.12. Thailand
  • 12.13. Vietnam

13. Europe, Middle East & Africa Critical Care Therapeutics Market

  • 13.1. Introduction
  • 13.2. Denmark
  • 13.3. Egypt
  • 13.4. Finland
  • 13.5. France
  • 13.6. Germany
  • 13.7. Israel
  • 13.8. Italy
  • 13.9. Netherlands
  • 13.10. Nigeria
  • 13.11. Norway
  • 13.12. Poland
  • 13.13. Qatar
  • 13.14. Russia
  • 13.15. Saudi Arabia
  • 13.16. South Africa
  • 13.17. Spain
  • 13.18. Sweden
  • 13.19. Switzerland
  • 13.20. Turkey
  • 13.21. United Arab Emirates
  • 13.22. United Kingdom

14. Competitive Landscape

  • 14.1. Market Share Analysis, 2024
  • 14.2. FPNV Positioning Matrix, 2024
  • 14.3. Competitive Scenario Analysis
    • 14.3.1. Mankind Pharma's transformative acquisition of Bharat Serums
    • 14.3.2. Poly Medicure targets international expansion in critical care with significant investment and strategic acquisitions
    • 14.3.3. BD enhances smart connected care through strategic acquisition of Edwards Lifesciences' critical care unit
  • 14.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Abeona Therapeutics Inc.
  • 2. ADMA Biologics, Inc.
  • 3. Albumedix Ltd. by Sartorius AG
  • 4. Asklepios BioPharmaceutical, Inc.
  • 5. Aspen Group
  • 6. Bio Products Laboratory Ltd.
  • 7. BioDelivery Sciences International, Inc.
  • 8. Biotest AG
  • 9. CSL Limited
  • 10. Grifols SA
  • 11. Kedrion Spa
  • 12. Novartis AG
  • 13. Octapharma AG
  • 14. Shanghai RAAS
  • 15. Takeda Pharmaceutical Co. Ltd.

LIST OF FIGURES

  • FIGURE 1. CRITICAL CARE THERAPEUTICS MARKET MULTI-CURRENCY
  • FIGURE 2. CRITICAL CARE THERAPEUTICS MARKET MULTI-LANGUAGE
  • FIGURE 3. CRITICAL CARE THERAPEUTICS MARKET RESEARCH PROCESS
  • FIGURE 4. CRITICAL CARE THERAPEUTICS MARKET SIZE, 2024 VS 2030
  • FIGURE 5. GLOBAL CRITICAL CARE THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 6. GLOBAL CRITICAL CARE THERAPEUTICS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 7. GLOBAL CRITICAL CARE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL CRITICAL CARE THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2030 (%)
  • FIGURE 9. GLOBAL CRITICAL CARE THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL CRITICAL CARE THERAPEUTICS MARKET SIZE, BY ADMINISTRATION ROUTES, 2024 VS 2030 (%)
  • FIGURE 11. GLOBAL CRITICAL CARE THERAPEUTICS MARKET SIZE, BY ADMINISTRATION ROUTES, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL CRITICAL CARE THERAPEUTICS MARKET SIZE, BY DRUG TYPES, 2024 VS 2030 (%)
  • FIGURE 13. GLOBAL CRITICAL CARE THERAPEUTICS MARKET SIZE, BY DRUG TYPES, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 14. GLOBAL CRITICAL CARE THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2024 VS 2030 (%)
  • FIGURE 15. GLOBAL CRITICAL CARE THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 16. GLOBAL CRITICAL CARE THERAPEUTICS MARKET SIZE, BY END-USER, 2024 VS 2030 (%)
  • FIGURE 17. GLOBAL CRITICAL CARE THERAPEUTICS MARKET SIZE, BY END-USER, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 18. AMERICAS CRITICAL CARE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 19. AMERICAS CRITICAL CARE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 20. UNITED STATES CRITICAL CARE THERAPEUTICS MARKET SIZE, BY STATE, 2024 VS 2030 (%)
  • FIGURE 21. UNITED STATES CRITICAL CARE THERAPEUTICS MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 22. ASIA-PACIFIC CRITICAL CARE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 23. ASIA-PACIFIC CRITICAL CARE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 24. EUROPE, MIDDLE EAST & AFRICA CRITICAL CARE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 25. EUROPE, MIDDLE EAST & AFRICA CRITICAL CARE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 26. CRITICAL CARE THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 27. CRITICAL CARE THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. CRITICAL CARE THERAPEUTICS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL CRITICAL CARE THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL CRITICAL CARE THERAPEUTICS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL CRITICAL CARE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. CRITICAL CARE THERAPEUTICS MARKET DYNAMICS
  • TABLE 7. GLOBAL CRITICAL CARE THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL CRITICAL CARE THERAPEUTICS MARKET SIZE, BY IMPLANTABLE DEVICES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL CRITICAL CARE THERAPEUTICS MARKET SIZE, BY INTRAVENOUS INFUSION BAGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL CRITICAL CARE THERAPEUTICS MARKET SIZE, BY MEDICATIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL CRITICAL CARE THERAPEUTICS MARKET SIZE, BY ANTIBIOTICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL CRITICAL CARE THERAPEUTICS MARKET SIZE, BY NEUROMUSCULAR BLOCKERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL CRITICAL CARE THERAPEUTICS MARKET SIZE, BY SEDATIVES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL CRITICAL CARE THERAPEUTICS MARKET SIZE, BY THROMBOLYTICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL CRITICAL CARE THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL CRITICAL CARE THERAPEUTICS MARKET SIZE, BY MONITORING DEVICES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL CRITICAL CARE THERAPEUTICS MARKET SIZE, BY SYRINGES & CATHETERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL CRITICAL CARE THERAPEUTICS MARKET SIZE, BY VENTILATORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL CRITICAL CARE THERAPEUTICS MARKET SIZE, BY ADMINISTRATION ROUTES, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL CRITICAL CARE THERAPEUTICS MARKET SIZE, BY INHALATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL CRITICAL CARE THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL CRITICAL CARE THERAPEUTICS MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL CRITICAL CARE THERAPEUTICS MARKET SIZE, BY DRUG TYPES, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL CRITICAL CARE THERAPEUTICS MARKET SIZE, BY ANALGESICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL CRITICAL CARE THERAPEUTICS MARKET SIZE, BY NON-OPIOID ANALGESICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL CRITICAL CARE THERAPEUTICS MARKET SIZE, BY OPIOID ANALGESICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL CRITICAL CARE THERAPEUTICS MARKET SIZE, BY ANALGESICS, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL CRITICAL CARE THERAPEUTICS MARKET SIZE, BY ANTIMICROBIALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 29. GLOBAL CRITICAL CARE THERAPEUTICS MARKET SIZE, BY ANTIBIOTICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 30. GLOBAL CRITICAL CARE THERAPEUTICS MARKET SIZE, BY BROAD-SPECTRUM ANTIBIOTICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 31. GLOBAL CRITICAL CARE THERAPEUTICS MARKET SIZE, BY NARROW-SPECTRUM ANTIBIOTICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 32. GLOBAL CRITICAL CARE THERAPEUTICS MARKET SIZE, BY ANTIBIOTICS, 2018-2030 (USD MILLION)
  • TABLE 33. GLOBAL CRITICAL CARE THERAPEUTICS MARKET SIZE, BY ANTIVIRALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 34. GLOBAL CRITICAL CARE THERAPEUTICS MARKET SIZE, BY ANTIMICROBIALS, 2018-2030 (USD MILLION)
  • TABLE 35. GLOBAL CRITICAL CARE THERAPEUTICS MARKET SIZE, BY SEDATIVES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 36. GLOBAL CRITICAL CARE THERAPEUTICS MARKET SIZE, BY BENZODIAZEPINES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 37. GLOBAL CRITICAL CARE THERAPEUTICS MARKET SIZE, BY NON-BENZODIAZEPINE SEDATIVES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 38. GLOBAL CRITICAL CARE THERAPEUTICS MARKET SIZE, BY SEDATIVES, 2018-2030 (USD MILLION)
  • TABLE 39. GLOBAL CRITICAL CARE THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 40. GLOBAL CRITICAL CARE THERAPEUTICS MARKET SIZE, BY CARDIOVASCULAR CARE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 41. GLOBAL CRITICAL CARE THERAPEUTICS MARKET SIZE, BY EMERGENCY RESUSCITATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 42. GLOBAL CRITICAL CARE THERAPEUTICS MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 43. GLOBAL CRITICAL CARE THERAPEUTICS MARKET SIZE, BY INTRACRANIAL PRESSURE MONITORING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 44. GLOBAL CRITICAL CARE THERAPEUTICS MARKET SIZE, BY TRAUMATIC BRAIN INJURY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 45. GLOBAL CRITICAL CARE THERAPEUTICS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 46. GLOBAL CRITICAL CARE THERAPEUTICS MARKET SIZE, BY RENAL REPLACEMENT THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 47. GLOBAL CRITICAL CARE THERAPEUTICS MARKET SIZE, BY RESPIRATORY CARE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 48. GLOBAL CRITICAL CARE THERAPEUTICS MARKET SIZE, BY ASTHMA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 49. GLOBAL CRITICAL CARE THERAPEUTICS MARKET SIZE, BY CHRONIC OBSTRUCTIVE PULMONARY DISEASE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 50. GLOBAL CRITICAL CARE THERAPEUTICS MARKET SIZE, BY PULMONARY EDEMA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 51. GLOBAL CRITICAL CARE THERAPEUTICS MARKET SIZE, BY RESPIRATORY CARE, 2018-2030 (USD MILLION)
  • TABLE 52. GLOBAL CRITICAL CARE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 53. GLOBAL CRITICAL CARE THERAPEUTICS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 54. GLOBAL CRITICAL CARE THERAPEUTICS MARKET SIZE, BY HOME HEALTHCARE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 55. GLOBAL CRITICAL CARE THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 56. GLOBAL CRITICAL CARE THERAPEUTICS MARKET SIZE, BY LONG-TERM CARE FACILITIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 57. AMERICAS CRITICAL CARE THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 58. AMERICAS CRITICAL CARE THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 59. AMERICAS CRITICAL CARE THERAPEUTICS MARKET SIZE, BY ADMINISTRATION ROUTES, 2018-2030 (USD MILLION)
  • TABLE 60. AMERICAS CRITICAL CARE THERAPEUTICS MARKET SIZE, BY DRUG TYPES, 2018-2030 (USD MILLION)
  • TABLE 61. AMERICAS CRITICAL CARE THERAPEUTICS MARKET SIZE, BY ANALGESICS, 2018-2030 (USD MILLION)
  • TABLE 62. AMERICAS CRITICAL CARE THERAPEUTICS MARKET SIZE, BY ANTIMICROBIALS, 2018-2030 (USD MILLION)
  • TABLE 63. AMERICAS CRITICAL CARE THERAPEUTICS MARKET SIZE, BY ANTIBIOTICS, 2018-2030 (USD MILLION)
  • TABLE 64. AMERICAS CRITICAL CARE THERAPEUTICS MARKET SIZE, BY SEDATIVES, 2018-2030 (USD MILLION)
  • TABLE 65. AMERICAS CRITICAL CARE THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 66. AMERICAS CRITICAL CARE THERAPEUTICS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 67. AMERICAS CRITICAL CARE THERAPEUTICS MARKET SIZE, BY RESPIRATORY CARE, 2018-2030 (USD MILLION)
  • TABLE 68. AMERICAS CRITICAL CARE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 69. AMERICAS CRITICAL CARE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 70. ARGENTINA CRITICAL CARE THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 71. ARGENTINA CRITICAL CARE THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 72. ARGENTINA CRITICAL CARE THERAPEUTICS MARKET SIZE, BY ADMINISTRATION ROUTES, 2018-2030 (USD MILLION)
  • TABLE 73. ARGENTINA CRITICAL CARE THERAPEUTICS MARKET SIZE, BY DRUG TYPES, 2018-2030 (USD MILLION)
  • TABLE 74. ARGENTINA CRITICAL CARE THERAPEUTICS MARKET SIZE, BY ANALGESICS, 2018-2030 (USD MILLION)
  • TABLE 75. ARGENTINA CRITICAL CARE THERAPEUTICS MARKET SIZE, BY ANTIMICROBIALS, 2018-2030 (USD MILLION)
  • TABLE 76. ARGENTINA CRITICAL CARE THERAPEUTICS MARKET SIZE, BY ANTIBIOTICS, 2018-2030 (USD MILLION)
  • TABLE 77. ARGENTINA CRITICAL CARE THERAPEUTICS MARKET SIZE, BY SEDATIVES, 2018-2030 (USD MILLION)
  • TABLE 78. ARGENTINA CRITICAL CARE THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 79. ARGENTINA CRITICAL CARE THERAPEUTICS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 80. ARGENTINA CRITICAL CARE THERAPEUTICS MARKET SIZE, BY RESPIRATORY CARE, 2018-2030 (USD MILLION)
  • TABLE 81. ARGENTINA CRITICAL CARE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 82. BRAZIL CRITICAL CARE THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 83. BRAZIL CRITICAL CARE THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 84. BRAZIL CRITICAL CARE THERAPEUTICS MARKET SIZE, BY ADMINISTRATION ROUTES, 2018-2030 (USD MILLION)
  • TABLE 85. BRAZIL CRITICAL CARE THERAPEUTICS MARKET SIZE, BY DRUG TYPES, 2018-2030 (USD MILLION)
  • TABLE 86. BRAZIL CRITICAL CARE THERAPEUTICS MARKET SIZE, BY ANALGESICS, 2018-2030 (USD MILLION)
  • TABLE 87. BRAZIL CRITICAL CARE THERAPEUTICS MARKET SIZE, BY ANTIMICROBIALS, 2018-2030 (USD MILLION)
  • TABLE 88. BRAZIL CRITICAL CARE THERAPEUTICS MARKET SIZE, BY ANTIBIOTICS, 2018-2030 (USD MILLION)
  • TABLE 89. BRAZIL CRITICAL CARE THERAPEUTICS MARKET SIZE, BY SEDATIVES, 2018-2030 (USD MILLION)
  • TABLE 90. BRAZIL CRITICAL CARE THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 91. BRAZIL CRITICAL CARE THERAPEUTICS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 92. BRAZIL CRITICAL CARE THERAPEUTICS MARKET SIZE, BY RESPIRATORY CARE, 2018-2030 (USD MILLION)
  • TABLE 93. BRAZIL CRITICAL CARE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 94. CANADA CRITICAL CARE THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 95. CANADA CRITICAL CARE THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 96. CANADA CRITICAL CARE THERAPEUTICS MARKET SIZE, BY ADMINISTRATION ROUTES, 2018-2030 (USD MILLION)
  • TABLE 97. CANADA CRITICAL CARE THERAPEUTICS MARKET SIZE, BY DRUG TYPES, 2018-2030 (USD MILLION)
  • TABLE 98. CANADA CRITICAL CARE THERAPEUTICS MARKET SIZE, BY ANALGESICS, 2018-2030 (USD MILLION)
  • TABLE 99. CANADA CRITICAL CARE THERAPEUTICS MARKET SIZE, BY ANTIMICROBIALS, 2018-2030 (USD MILLION)
  • TABLE 100. CANADA CRITICAL CARE THERAPEUTICS MARKET SIZE, BY ANTIBIOTICS, 2018-2030 (USD MILLION)
  • TABLE 101. CANADA CRITICAL CARE THERAPEUTICS MARKET SIZE, BY SEDATIVES, 2018-2030 (USD MILLION)
  • TABLE 102. CANADA CRITICAL CARE THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 103. CANADA CRITICAL CARE THERAPEUTICS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 104. CANADA CRITICAL CARE THERAPEUTICS MARKET SIZE, BY RESPIRATORY CARE, 2018-2030 (USD MILLION)
  • TABLE 105. CANADA CRITICAL CARE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 106. MEXICO CRITICAL CARE THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 107. MEXICO CRITICAL CARE THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 108. MEXICO CRITICAL CARE THERAPEUTICS MARKET SIZE, BY ADMINISTRATION ROUTES, 2018-2030 (USD MILLION)
  • TABLE 109. MEXICO CRITICAL CARE THERAPEUTICS MARKET SIZE, BY DRUG TYPES, 2018-2030 (USD MILLION)
  • TABLE 110. MEXICO CRITICAL CARE THERAPEUTICS MARKET SIZE, BY ANALGESICS, 2018-2030 (USD MILLION)
  • TABLE 111. MEXICO CRITICAL CARE THERAPEUTICS MARKET SIZE, BY ANTIMICROBIALS, 2018-2030 (USD MILLION)
  • TABLE 112. MEXICO CRITICAL CARE THERAPEUTICS MARKET SIZE, BY ANTIBIOTICS, 2018-2030 (USD MILLION)
  • TABLE 113. MEXICO CRITICAL CARE THERAPEUTICS MARKET SIZE, BY SEDATIVES, 2018-2030 (USD MILLION)
  • TABLE 114. MEXICO CRITICAL CARE THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 115. MEXICO CRITICAL CARE THERAPEUTICS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 116. MEXICO CRITICAL CARE THERAPEUTICS MARKET SIZE, BY RESPIRATORY CARE, 2018-2030 (USD MILLION)
  • TABLE 117. MEXICO CRITICAL CARE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 118. UNITED STATES CRITICAL CARE THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 119. UNITED STATES CRITICAL CARE THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 120. UNITED STATES CRITICAL CARE THERAPEUTICS MARKET SIZE, BY ADMINISTRATION ROUTES, 2018-2030 (USD MILLION)
  • TABLE 121. UNITED STATES CRITICAL CARE THERAPEUTICS MARKET SIZE, BY DRUG TYPES, 2018-2030 (USD MILLION)
  • TABLE 122. UNITED STATES CRITICAL CARE THERAPEUTICS MARKET SIZE, BY ANALGESICS, 2018-2030 (USD MILLION)
  • TABLE 123. UNITED STATES CRITICAL CARE THERAPEUTICS MARKET SIZE, BY ANTIMICROBIALS, 2018-2030 (USD MILLION)
  • TABLE 124. UNITED STATES CRITICAL CARE THERAPEUTICS MARKET SIZE, BY ANTIBIOTICS, 2018-2030 (USD MILLION)
  • TABLE 125. UNITED STATES CRITICAL CARE THERAPEUTICS MARKET SIZE, BY SEDATIVES, 2018-2030 (USD MILLION)
  • TABLE 126. UNITED STATES CRITICAL CARE THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 127. UNITED STATES CRITICAL CARE THERAPEUTICS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 128. UNITED STATES CRITICAL CARE THERAPEUTICS MARKET SIZE, BY RESPIRATORY CARE, 2018-2030 (USD MILLION)
  • TABLE 129. UNITED STATES CRITICAL CARE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 130. UNITED STATES CRITICAL CARE THERAPEUTICS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 131. ASIA-PACIFIC CRITICAL CARE THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 132. ASIA-PACIFIC CRITICAL CARE THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 133. ASIA-PACIFIC CRITICAL CARE THERAPEUTICS MARKET SIZE, BY ADMINISTRATION ROUTES, 2018-2030 (USD MILLION)
  • TABLE 134. ASIA-PACIFIC CRITICAL CARE THERAPEUTICS MARKET SIZE, BY DRUG TYPES, 2018-2030 (USD MILLION)
  • TABLE 135. ASIA-PACIFIC CRITICAL CARE THERAPEUTICS MARKET SIZE, BY ANALGESICS, 2018-2030 (USD MILLION)
  • TABLE 136. ASIA-PACIFIC CRITICAL CARE THERAPEUTICS MARKET SIZE, BY ANTIMICROBIALS, 2018-2030 (USD MILLION)
  • TABLE 137. ASIA-PACIFIC CRITICAL CARE THERAPEUTICS MARKET SIZE, BY ANTIBIOTICS, 2018-2030 (USD MILLION)
  • TABLE 138. ASIA-PACIFIC CRITICAL CARE THERAPEUTICS MARKET SIZE, BY SEDATIVES, 2018-2030 (USD MILLION)
  • TABLE 139. ASIA-PACIFIC CRITICAL CARE THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 140. ASIA-PACIFIC CRITICAL CARE THERAPEUTICS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 141. ASIA-PACIFIC CRITICAL CARE THERAPEUTICS MARKET SIZE, BY RESPIRATORY CARE, 2018-2030 (USD MILLION)
  • TABLE 142. ASIA-PACIFIC CRITICAL CARE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 143. ASIA-PACIFIC CRITICAL CARE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 144. AUSTRALIA CRITICAL CARE THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 145. AUSTRALIA CRITICAL CARE THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 146. AUSTRALIA CRITICAL CARE THERAPEUTICS MARKET SIZE, BY ADMINISTRATION ROUTES, 2018-2030 (USD MILLION)
  • TABLE 147. AUSTRALIA CRITICAL CARE THERAPEUTICS MARKET SIZE, BY DRUG TYPES, 2018-2030 (USD MILLION)
  • TABLE 148. AUSTRALIA CRITICAL CARE THERAPEUTICS MARKET SIZE, BY ANALGESICS, 2018-2030 (USD MILLION)
  • TABLE 149. AUSTRALIA CRITICAL CARE THERAPEUTICS MARKET SIZE, BY ANTIMICROBIALS, 2018-2030 (USD MILLION)
  • TABLE 150. AUSTRALIA CRITICAL CARE THERAPEUTICS MARKET SIZE, BY ANTIBIOTICS, 2018-2030 (USD MILLION)
  • TABLE 151. AUSTRALIA CRITICAL CARE THERAPEUTICS MARKET SIZE, BY SEDATIVES, 2018-2030 (USD MILLION)
  • TABLE 152. AUSTRALIA CRITICAL CARE THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 153. AUSTRALIA CRITICAL CARE THERAPEUTICS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 154. AUSTRALIA CRITICAL CARE THERAPEUTICS MARKET SIZE, BY RESPIRATORY CARE, 2018-2030 (USD MILLION)
  • TABLE 155. AUSTRALIA CRITICAL CARE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 156. CHINA CRITICAL CARE THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 157. CHINA CRITICAL CARE THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 158. CHINA CRITICAL CARE THERAPEUTICS MARKET SIZE, BY ADMINISTRATION ROUTES, 2018-2030 (USD MILLION)
  • TABLE 159. CHINA CRITICAL CARE THERAPEUTICS MARKET SIZE, BY DRUG TYPES, 2018-2030 (USD MILLION)
  • TABLE 160. CHINA CRITICAL CARE THERAPEUTICS MARKET SIZE, BY ANALGESICS, 2018-2030 (USD MILLION)
  • TABLE 161. CHINA CRITICAL CARE THERAPEUTICS MARKET SIZE, BY ANTIMICROBIALS, 2018-2030 (USD MILLION)
  • TABLE 162. CHINA CRITICAL CARE THERAPEUTICS MARKET SIZE, BY ANTIBIOTICS, 2018-2030 (USD MILLION)
  • TABLE 163. CHINA CRITICAL CARE THERAPEUTICS MARKET SIZE, BY SEDATIVES, 2018-2030 (USD MILLION)
  • TABLE 164. CHINA CRITICAL CARE THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 165. CHINA CRITICAL CARE THERAPEUTICS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 166. CHINA CRITICAL CARE THERAPEUTICS MARKET SIZE, BY RESPIRATORY CARE, 2018-2030 (USD MILLION)
  • TABLE 167. CHINA CRITICAL CARE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 168. INDIA CRITICAL CARE THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 169. INDIA CRITICAL CARE THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 170. INDIA CRITICAL CARE THERAPEUTICS MARKET SIZE, BY ADMINISTRATION ROUTES, 2018-2030 (USD MILLION)
  • TABLE 171. INDIA CRITICAL CARE THERAPEUTICS MARKET SIZE, BY DRUG TYPES, 2018-2030 (USD MILLION)
  • TABLE 172. INDIA CRITICAL CARE THERAPEUTICS MARKET SIZE, BY ANALGESICS, 2018-2030 (USD MILLION)
  • TABLE 173. INDIA CRITICAL CARE THERAPEUTICS MARKET SIZE, BY ANTIMICROBIALS, 2018-2030 (USD MILLION)
  • TABLE 174. INDIA CRITICAL CARE THERAPEUTICS MARKET SIZE, BY ANTIBIOTICS, 2018-2030 (USD MILLION)
  • TABLE 175. INDIA CRITICAL CARE THERAPEUTICS MARKET SIZE, BY SEDATIVES, 2018-2030 (USD MILLION)
  • TABLE 176. INDIA CRITICAL CARE THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 177. INDIA CRITICAL CARE THERAPEUTICS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 178. INDIA CRITICAL CARE THERAPEUTICS MARKET SIZE, BY RESPIRATORY CARE, 2018-2030 (USD MILLION)
  • TABLE 179. INDIA CRITICAL CARE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 180. INDONESIA CRITICAL CARE THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 181. INDONESIA CRITICAL CARE THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 182. INDONESIA CRITICAL CARE THERAPEUTICS MARKET SIZE, BY ADMINISTRATION ROUTES, 2018-2030 (USD MILLION)
  • TABLE 183. INDONESIA CRITICAL CARE THERAPEUTICS MARKET SIZE, BY DRUG TYPES, 2018-2030 (USD MILLION)
  • TABLE 184. INDONESIA CRITICAL CARE THERAPEUTICS MARKET SIZE, BY ANALGESICS, 2018-2030 (USD MILLION)
  • TABLE 185. INDONESIA CRITICAL CARE THERAPEUTICS MARKET SIZE, BY ANTIMICROBIALS, 2018-2030 (USD MILLION)
  • TABLE 186. INDONESIA CRITICAL CARE THERAPEUTICS MARKET SIZE, BY ANTIBIOTICS, 2018-2030 (USD MILLION)
  • TABLE 187. INDONESIA CRITICAL CARE THERAPEUTICS MARKET SIZE, BY SEDATIVES, 2018-2030 (USD MILLION)
  • TABLE 188. INDONESIA CRITICAL CARE THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 189. INDONESIA CRITICAL CARE THERAPEUTICS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 190. INDONESIA CRITICAL CARE THERAPEUTICS MARKET SIZE, BY RESPIRATORY CARE, 2018-2030 (USD MILLION)
  • TABLE 191. INDONESIA CRITICAL CARE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 192. JAPAN CRITICAL CARE THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 193. JAPAN CRITICAL CARE THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 194. JAPAN CRITICAL CARE THERAPEUTICS MARKET SIZE, BY ADMINISTRATION ROUTES, 2018-2030 (USD MILLION)
  • TABLE 195. JAPAN CRITICAL CARE THERAPEUTICS MARKET SIZE, BY DRUG TYPES, 2018-2030 (USD MILLION)
  • TABLE 196. JAPAN CRITICAL CARE THERAPEUTICS MARKET SIZE, BY ANALGESICS, 2018-2030 (USD MILLION)
  • TABLE 197. JAPAN CRITICAL CARE THERAPEUTICS MARKET SIZE, BY ANTIMICROBIALS, 2018-2030 (USD MILLION)
  • TABLE 198. JAPAN CRITICAL CARE THERAPEUTICS MARKET SIZE, BY ANTIBIOTICS, 2018-2030 (USD MILLION)
  • TABLE 199. JAPAN CRITICAL CARE THERAPEUTICS MARKET SIZE, BY SEDATIVES, 2018-2030 (USD MILLION)
  • TABLE 200. JAPAN CRITICAL CARE THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 201. JAPAN CRITICAL CARE THERAPEUTICS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 202. JAPAN CRITICAL CARE THERAPEUTICS MARKET SIZE, BY RESPIRATORY CARE, 2018-2030 (USD MILLION)
  • TABLE 203. JAPAN CRITICAL CARE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 204. MALAYSIA CRITICAL CARE THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 205. MALAYSIA CRITICAL CARE THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 206. MALAYSIA CRITICAL CARE THERAPEUTICS MARKET SIZE, BY ADMINISTRATION ROUTES, 2018-2030 (USD MILLION)
  • TABLE 207. MALAYSIA CRITICAL CARE THERAPEUTICS MARKET SIZE, BY DRUG TYPES, 2018-2030 (USD MILLION)
  • TABLE 208. MALAYSIA CRITICAL CARE THERAPEUTICS MARKET SIZE, BY ANALGESICS, 2018-2030 (USD MILLION)
  • TABLE 209. MALAYSIA CRITICAL CARE THERAPEUTICS MARKET SIZE, BY ANTIMICROBIALS, 2018-2030 (USD MILLION)
  • TABLE 210. MALAYSIA CRITICAL CARE THERAPEUTICS MARKET SIZE, BY ANTIBIOTICS, 2018-2030 (USD MILLION)
  • TABLE 211. MALAYSIA CRITICAL CARE THERAPEUTICS MARKET SIZE, BY SEDATIVES, 2018-2030 (USD MILLION)
  • TABLE 212. MALAYSIA CRITICAL CARE THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 213. MALAYSIA CRITICAL CARE THERAPEUTICS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 214. MALAYSIA CRITICAL CARE THERAPEUTICS MARKET SIZE, BY RESPIRATORY CARE, 2018-2030 (USD MILLION)
  • TABLE 215. MALAYSIA CRITICAL CARE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 216. PHILIPPINES CRITICAL CARE THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 217. PHILIPPINES CRITICAL CARE THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 218. PHILIPPINES CRITICAL CARE THERAPEUTICS MARKET SIZE, BY ADMINISTRATION ROUTES, 2018-2030 (USD MILLION)
  • TABLE 219. PHILIPPINES CRITICAL CARE THERAPEUTICS MARKET SIZE, BY DRUG TYPES, 2018-2030 (USD MILLION)
  • TABLE 220. PHILIPPINES CRITICAL CARE THERAPEUTICS MARKET SIZE, BY ANALGESICS, 2018-2030 (USD MILLION)
  • TABLE 221. PHILIPPINES CRITICAL CARE THERAPEUTICS MARKET SIZE, BY ANTIMICROBIALS, 2018-2030 (USD MILLION)
  • TABLE 222. PHILIPPINES CRITICAL CARE THERAPEUTICS MARKET SIZE, BY ANTIBIOTICS, 2018-2030 (USD MILLION)
  • TABLE 223. PHILIPPINES CRITICAL CARE THERAPEUTICS MARKET SIZE, BY SEDATIVES, 2018-2030 (USD MILLION)
  • TABLE 224. PHILIPPINES CRITICAL CARE THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 225. PHILIPPINES CRITICAL CARE THERAPEUTICS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 226. PHILIPPINES CRITICAL CARE THERAPEUTICS MARKET SIZE, BY RESPIRATORY CARE, 2018-2030 (USD MILLION)
  • TABLE 227. PHILIPPINES CRITICAL CARE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 228. SINGAPORE CRITICAL CARE THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 229. SINGAPORE CRITICAL CARE THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 230. SINGAPORE CRITICAL CARE THERAPEUTICS MARKET SIZE, BY ADMINISTRATION ROUTES, 2018-2030 (USD MILLION)
  • TABLE 231. SINGAPORE CRITICAL CARE THERAPEUTICS MARKET SIZE, BY DRUG TYPES, 2018-2030 (USD MILLION)
  • TABLE 232. SINGAPORE CRITICAL CARE THERAPEUTICS MARKET SIZE, BY ANALGESICS, 2018-2030 (USD MILLION)
  • TABLE 233. SINGAPORE CRITICAL CARE THERAPEUTICS MARKET SIZE, BY ANTIMICROBIALS, 2018-2030 (USD MILLION)
  • TABLE 234. SINGAPORE CRITICAL CARE THERAPEUTICS MARKET SIZE, BY ANTIBIOTICS, 2018-2030 (USD MILLION)
  • TABLE 235. SINGAPORE CRITICAL CARE THERAPEUTICS MARKET SIZE, BY SEDATIVES, 2018-2030 (USD MILLION)
  • TABLE 236. SINGAPORE CRITICAL CARE THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 237. SINGAPORE CRITICAL CARE THERAPEUTICS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 238. SINGAPORE CRITICAL CARE THERAPEUTICS MARKET SIZE, BY RESPIRATORY CARE, 2018-2030 (USD MILLION)
  • TABLE 239. SINGAPORE CRITICAL CARE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 240. SOUTH KOREA CRITICAL CARE THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 241. SOUTH KOREA CRITICAL CARE THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 242. SOUTH KOREA CRITICAL CARE THERAPEUTICS MARKET SIZE, BY ADMINISTRATION ROUTES, 2018-2030 (USD MILLION)
  • TABLE 243. SOUTH KOREA CRITICAL CARE THERAPEUTICS MARKET SIZE, BY DRUG TYPES, 2018-2030 (USD MILLION)
  • TABLE 244. SOUTH KOREA CRITICAL CARE THERAPEUTICS MARKET SIZE, BY ANALGESICS, 2018-2030 (USD MILLION)
  • TABLE 245. SOUTH KOREA CRITICAL CARE THERAPEUTICS MARKET SIZE, BY ANTIMICROBIALS, 2018-2030 (USD MILLION)
  • TABLE 246. SOUTH KOREA CRITICAL CARE THERAPEUTICS MARKET SIZE, BY ANTIBIOTICS, 2018-2030 (USD MILLION)
  • TABLE 247. SOUTH KOREA CRITICAL CARE THERAPEUTICS MARKET SIZE, BY SEDATIVES, 2018-2030 (USD MILLION)
  • TABLE 248. SOUTH KOREA CRITICAL CARE THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 249. SOUTH KOREA CRITICAL CARE THERAPEUTICS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 250. SOUTH KOREA CRITICAL CARE THERAPEUTICS MARKET SIZE, BY RESPIRATORY CARE, 2018-2030 (USD MILLION)
  • TABLE 251. SOUTH KOREA CRITICAL CARE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 252. TAIWAN CRITICAL CARE THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 253. TAIWAN CRITICAL CARE THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 254. TAIWAN CRITICAL CARE THERAPEUTICS MARKET SIZE, BY ADMINISTRATION ROUTES, 2018-2030 (USD MILLION)
  • TABLE 255. TAIWAN CRITICAL CARE THERAPEUTICS MARKET SIZE, BY DRUG TYPES, 2018-2030 (USD MILLION)
  • TABLE 256. TAIWAN CRITICAL CARE THERAPEUTICS MARKET SIZE, BY ANALGESICS, 2018-2030 (USD MILLION)
  • TABLE 257. TAIWAN CRITICAL CARE THERAPEUTICS MARKET SIZE, BY ANTIMICROBIALS, 2018-2030 (USD MILLION)
  • TABLE 258. TAIWAN CRITICAL CARE THERAPEUTICS MARKET SIZE, BY ANTIBIOTICS, 2018-2030 (USD MILLION)
  • TABLE 259. TAIWAN CRITICAL CARE THERAPEUTICS MARKET SIZE, BY SEDATIVES, 2018-2030 (USD MILLION)
  • TABLE 260. TAIWAN CRITICAL CARE THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 261. TAIWAN CRITICAL CARE THERAPEUTICS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 262. TAIWAN CRITICAL CARE THERAPEUTICS MARKET SIZE, BY RESPIRATORY CARE, 2018-2030 (USD MILLION)
  • TABLE 263. TAIWAN CRITICAL CARE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 264. THAILAND CRITICAL CARE THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 265. THAILAND CRITICAL CARE THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 266. THAILAND CRITICAL CARE THERAPEUTICS MARKET SIZE, BY ADMINISTRATION ROUTES, 2018-2030 (USD MILLION)
  • TABLE 267. THAILAND CRITICAL CARE THERAPEUTICS MARKET SIZE, BY DRUG TYPES, 2018-2030 (USD MILLION)
  • TABLE 268. THAILAND CRITICAL CARE THERAPEUTICS MARKET SIZE, BY ANALGESICS, 2018-2030 (USD MILLION)
  • TABLE 269. THAILAND CRITICAL CARE THERAPEUTICS MARKET SIZE, BY ANTIMICROBIALS, 2018-2030 (USD MILLION)
  • TABLE 270. THAILAND CRITICAL CARE THERAPEUTICS MARKET SIZE, BY ANTIBIOTICS, 2018-2030 (USD MILLION)
  • TABLE 271. THAILAND CRITICAL CARE THERAPEUTICS MARKET SIZE, BY SEDATIVES, 2018-2030 (USD MILLION)
  • TABLE 272. THAILAND CRITICAL CARE THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 273. THAILAND CRITICAL CARE THERAPEUTICS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 274. THAILAND CRITICAL CARE THERAPEUTICS MARKET SIZE, BY RESPIRATORY CARE, 2018-2030 (USD MILLION)
  • TABLE 275. THAILAND CRITICAL CARE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 276. VIETNAM CRITICAL CARE THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 277. VIETNAM CRITICAL CARE THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 278. VIETNAM CRITICAL CARE THERAPEUTICS MARKET SIZE, BY ADMINISTRATION ROUTES, 2018-2030 (USD MILLION)
  • TABLE 279. VIETNAM CRITICAL CARE THERAPEUTICS MARKET SIZE, BY DRUG TYPES, 2018-2030 (USD MILLION)
  • TABLE 280. VIETNAM CRITICAL CARE THERAPEUTICS MARKET SIZE, BY ANALGESICS, 2018-2030 (USD MILLION)
  • TABLE 281. VIETNAM CRITICAL CARE THERAPEUTICS MARKET SIZE, BY ANTIMICROBIALS, 2018-2030 (USD MILLION)
  • TABLE 282. VIETNAM CRITICAL CARE THERAPEUTICS MARKET SIZE, BY ANTIBIOTICS, 2018-2030 (USD MILLION)
  • TABLE 283. VIETNAM CRITICAL CARE THERAPEUTICS MARKET SIZE, BY SEDATIVES, 2018-2030 (USD MILLION)
  • TABLE 284. VIETNAM CRITICAL CARE THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 285. VIETNAM CRITICAL CARE THERAPEUTICS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 286. VIETNAM CRITICAL CARE THERAPEUTICS MARKET SIZE, BY RESPIRATORY CARE, 2018-2030 (USD MILLION)
  • TABLE 287. VIETNAM CRITICAL CARE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 288. EUROPE, MIDDLE EAST & AFRICA CRITICAL CARE THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 289. EUROPE, MIDDLE EAST & AFRICA CRITICAL CARE THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 290. EUROPE, MIDDLE EAST & AFRICA CRITICAL CARE THERAPEUTICS MARKET SIZE, BY ADMINISTRATION ROUTES, 2018-2030 (USD MILLION)
  • TABLE 291. EUROPE, MIDDLE EAST & AFRICA CRITICAL CARE THERAPEUTICS MARKET SIZE, BY DRUG TYPES, 2018-2030 (USD MILLION)
  • TABLE 292. EUROPE, MIDDLE EAST & AFRICA CRITICAL CARE THERAPEUTICS MARKET SIZE, BY ANALGESICS, 2018-2030 (USD MILLION)
  • TABLE 293. EUROPE, MIDDLE EAST & AFRICA CRITICAL CARE THERAPEUTICS MARKET SIZE, BY ANTIMICROBIALS, 2018-2030 (USD MILLION)
  • TABLE 294. EUROPE, MIDDLE EAST & AFRICA CRITICAL CARE THERAPEUTICS MARKET SIZE, BY ANTIBIOTICS, 2018-2030 (USD MILLION)
  • TABLE 295. EUROPE, MIDDLE EAST & AFRICA CRITICAL CARE THERAPEUTICS MARKET SIZE, BY SEDATIVES, 2018-2030 (USD MILLION)
  • TABLE 296. EUROPE, MIDDLE EAST & AFRICA CRITICAL CARE THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 297. EUROPE, MIDDLE EAST & AFRICA CRITICAL CARE THERAPEUTICS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 298. EUROPE, MIDDLE EAST & AFRICA CRITICAL CARE THERAPEUTICS MARKET SIZE, BY RESPIRATORY CARE, 2018-2030 (USD MILLION)
  • TABLE 299. EUROPE, MIDDLE EAST & AFRICA CRITICAL CARE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 300. EUROPE, MIDDLE EAST & AFRICA CRITICAL CARE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 301. DENMARK CRITICAL CARE THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 302. DENMARK CRITICAL CARE THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 303. DENMARK CRITICAL CARE THERAPEUTICS MARKET SIZE, BY ADMINISTRATION ROUTES, 2018-2030 (USD MILLION)
  • TABLE 304. DENMARK CRITICAL CARE THERAPEUTICS MARKET SIZE, BY DRUG TYPES, 2018-2030 (USD MILLION)
  • TABLE 305. DENMARK CRITICAL CARE THERAPEUTICS MARKET SIZE, BY ANALGESICS, 2018-2030 (USD MILLION)
  • TABLE 306. DENMARK CRITICAL CARE THERAPEUTICS MARKET SIZE, BY ANTIMICROBIALS, 2018-2030 (USD MILLION)
  • TABLE 307. DENMARK CRITICAL CARE THERAPEUTICS MARKET SIZE, BY ANTIBIOTICS, 2018-2030 (USD MILLION)
  • TABLE 308. DENMARK CRITICAL CARE THERAPEUTICS MARKET SIZE, BY SEDATIVES, 2018-2030 (USD MILLION)
  • TABLE 309. DENMARK CRITICAL CARE THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 310. DENMARK CRITICAL CARE THERAPEUTICS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 311. DENMARK CRITICAL CARE THERAPEUTICS MARKET SIZE, BY RESPIRATORY CARE, 2018-2030 (USD MILLION)
  • TABLE 312. DENMARK CRITICAL CARE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 313. EGYPT CRITICAL CARE THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 314. EGYPT CRITICAL CARE THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 315. EGYPT CRITICAL CARE THERAPEUTICS